ReviewNature reviews. Microbiology2023
Crimean-Congo haemorrhagic fever virus.
Review in Nature reviews. Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 3 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Pooled it
- Tick Diversity, Emerging Tick-Borne Pathogens, and Public Health Implications Across Africa: A Systematic Review.Acta parasitologica · 2025Pooled it
- Systematic review and meta-analysis for the occurrence of Crimean-Congo hemorrhagic fever, Tularemia, and Rift Valley fever in pastoralist systems in Africa.Frontiers in veterinary science · 2025Pooled it
- Pathogenicity and virulence of Crimean-Congo hemorrhagic fever virus: From enzootic maintenance to severe human disease.Virulence · 2026Review
- The Crimean-Congo haemorrhagic fever virus hijacks the liver lipid metabolic pathway for virion production.Emerging microbes & infections · 2026Article
- Targeted cleavage site mutations in the Gn precursor enable efficient generation of replication-competent rVSV-based surrogates for emerging nairoviruses.Emerging microbes & infections · 2026Article
- Hantavirus seroprevalence and associated factors for exposure in south-central Uganda.Emerging microbes & infections · 2026Article
- Zoonotic arboviruses and associated risk factors in donkeys from northeastern Algeria.Tropical animal health and production · 2026Article
- Detection of Anaplasma capra in Patients with Suspected Crimean-Congo Hemorrhagic Fever, Turkey, 2022.Emerging infectious diseases · 2026Review
- Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity.Scientific reports · 2026Article
- Co-Endemic Zoonoses, Divergent Dynamics: A Comparative Spatiotemporal Analysis of Crimean-Congo Hemorrhagic Fever and Brucellosis with Implications for Integrated Surveillance.Tropical medicine and infectious disease · 2026Article
- Article
- Article
- Article
- Tick-borne viruses: discovery, clinical aspects, influencing factors and control.Nature reviews. Microbiology · 2026Review
- Viral dissemination and diagnostic insights from experimental infection of sheep with Crimean-Congo hemorrhagic fever virus.Npj viruses · 2026Article
- Structural and mechanistic insights into protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus nucleocapsid protein.Nature communications · 2026Article
- Side-by-side evaluation of two Crimean-Congo hemorrhagic fever virus isolates in IFNARNpj viruses · 2026Article
- Circular RNA Expression Profiles in Crimean-Congo Hemorrhagic Fever: Insights into Disease Pathogenesis and Fatal Outcomes.International journal of molecular sciences · 2026Article
- Structures of the Crimean-Congo hemorrhagic fever virus RNA-dependent RNA polymerase.Cell discovery · 2026Article
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Crimean-Congo haemorrhagic fever (CCHF) is a severe tick-borne illness with a wide geographical distribution and case fatality rates of 30% or higher. Caused by infection with the CCHF virus (CCHFV), cases are reported throughout Africa, the Middle East, Asia and southern and eastern Europe. The expanding range of the Hyalomma tick vector is placing new populations at risk for CCHF, and no licensed vaccines or specific antivirals exist to treat CCHF. Furthermore, despite cases of CCHF being reported annually, the host and viral determinants of CCHFV pathogenesis are poorly understood. CCHFV can productively infect a multitude of animal species, yet only humans develop a severe illness. Within human populations, subclinical infections are underappreciated and may represent a substantial proportion of clinical outcomes. Compared with other members of the Bunyavirales order, CCHFV has a more complex genomic organization, with many viral proteins having unclear functions in viral pathogenesis. In recent years, improved animal models have led to increased insights into CCHFV pathogenesis, and several antivirals and vaccines for CCHFV have shown robust efficacy in preclinical models. Translation of these insights and candidate therapeutics to the clinic will hopefully reduce the morbidity and mortality caused by CCHFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.